Biocytogen Grants Taisho Pharmaceutical License to RenNano® Antibody Platform

The deal allows Taisho to access Biocytogen's proprietary fully human heavy chain-only antibody discovery technology.

Mar. 30, 2026 at 11:53am

Got story updates? Submit your updates here. ›

Biocytogen Pharmaceuticals, a global biotech company, has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. that grants Taisho the right to access and use Biocytogen's proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs.

Why it matters

The RenNano® platform enables the efficient generation of fully human heavy-chain-only antibodies, which can be used to develop next-generation innovative therapeutics like bispecific antibodies, antibody-drug conjugates, and in vivo CAR-T therapies. This collaboration expands Biocytogen's global partnerships and helps establish a more efficient, fully human VHH discovery workflow for Taisho.

The details

Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed.

  • The agreement was announced on March 30, 2026.

The players

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

A global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies.

Taisho Pharmaceutical Co., Ltd.

A Japanese pharmaceutical company that will leverage Biocytogen's RenNano® platform for its internal research and development programs.

Got photos? Submit your photos here. ›

What they’re saying

“We are very pleased to enter into this collaboration with Taisho. RenNano® is a robust and powerful fully human VHH discovery platform that provides an ideal antibody foundation for the development of a broad range of next-generation innovative therapeutics. Through this collaboration, RenNano® will support Taisho's internal R&D efforts and help establish a more efficient, fully human VHH discovery workflow.”

— Dr. Yuelei Shen, President and CEO of Biocytogen

The takeaway

This collaboration further expands Biocytogen's growing portfolio of global partnerships and demonstrates the value of its proprietary RenNano® platform in enabling the efficient discovery of fully human heavy-chain-only antibodies for the development of innovative therapeutic modalities.